

# CD4<sup>+</sup> T cells in the blood of MS patients respond to predicted epitopes from B cell receptors found in spinal fluid

Rune A. Høglund<sup>1,2</sup>, A. Lossius<sup>1,2,3</sup>, E. J. Homan<sup>4</sup>, R. Bremel<sup>4</sup> and T. Holmøy<sup>1,2</sup>


<sup>1</sup>Department of Neurology, Akershus University Hospital, Lørenskog, Norway, <sup>2</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway, <sup>3</sup>Department of Immunology and Transfusion Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway, <sup>4</sup>ioGenetics LLC, Madison, WI, USA

## Introduction

The pathogenic role of B cells in multiple sclerosis (MS) is not known. We have previously demonstrated that B cells from cerebrospinal fluid (CSF) of MS patients can activate T cells through specific recognition of antigenic determinants (idiotopes) from their own B cells receptors (BCRs). The aim of this study was to evaluate these findings in MS patients using *in silico* prediction models to accurately and quickly identify immunogenic idiotopes of immunoglobulin heavy-chain variable (IGHV) gene repertoires.

## Materials and methods


Translated CSF IGHV repertoires were run through bioinformatic predictions *in silico* to predict HLA-DR affinity and endosomal processing, and calculate T cell exposed motif frequency. Predictions and transcript frequencies guided selection of idiotope-peptides from nine MS patients. PBMC from these patients were stimulated *in vitro* with the idiotope peptides in presence of anti-CD40 for 12 hours. Flow cytometry was utilized to identify activated cells using relevant surface makers (Table 1 and Figure 1). Unstimulated cells or insulin peptides were negative controls, and CD3/CD28 beads or EBNA-1 peptides were positive controls




**Figure 1.** A) IGHV amino acid sequences (1079 [SD=1213]) from MS patients were run through predictive models to identify likely antigenic or inert peptides. B) PBMC were stimulated with idiotope peptides. C) Activated CD4<sup>+</sup>CD45RO<sup>+</sup> memory T cells were detected by surface expression of CD154.

## Results

In all nine MS patients, we found blood memory CD4<sup>+</sup> T cells were activated by predicted idiotope-peptides (Figure 2). Responses were mainly towards peptides affiliated with the CDR3 region, and no robust responses were seen towards peptides with low predicted HLA-DR affinity. Activated memory CD4<sup>+</sup> T cells also expressed the chemokine receptor CCR6, affiliated with a Th17 phenotype and allowing passage into the central nervous system (Figure 3).



**Figure 2.** CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>-</sup> T cells were assayed for the activation marker CD154. Activated cells among all CD4<sup>+</sup> cells, CD45RO<sup>+</sup> memory- or CD45RO<sup>-</sup> naïve cells are presented as proportions of CD4<sup>+</sup> cells (upper three panels) or proportion of memory cells (lower panel). Responses were deemed positive (arrows) if the proportion of CD154<sup>+</sup> cells were 3x higher than in unstimulated (negative) wells.



**Figure 3.** CCR6 and CXCR3 expression among activated (CD154<sup>+</sup>) or un-activated (CD154<sup>-</sup>) memory (CD45RO<sup>+</sup>) CD4<sup>+</sup> T cells responding to predicted idiotope peptides. P-values are results of full factorial mixed model.

**Table 1: Surface markers and fluorochromes used in experiment**

Laser	Fluorochromes	Marker
407 nm (Violet)	BV421	CD154 (activation)
	PE	CXCR3
488 nm (Blue)	PE-Cy7	CD45RO (memory)
	PerCP-Cy5.5	CD4
	FITC	CD3
633 nm (Red)	APC	CCR6
	APC-H7	CD14
		CD8
	LIVE/DEAD™	Viability
	Fixable Near-IR	(dump channel)


## Conclusions

This *in vitro* study suggests that MS patients have a memory T cell repertoire capable of recognizing frequent BCRs found in endogenous CSF, and that these T cells express chemokine receptors allowing them to reach the B cells presenting these peptides. It further indicates that antigenic properties of BCR idiotopes can be predicted *in silico* using HLA affinity and endosomal processing predictions.

ioGenetics



UiO Institute of Clinical Medicine  
University of Oslo



AKERSHUS UNIVERSITY HOSPITAL

Disclosures: RDB and EJH holds equity in ioGenetics, the company responsible for designing the bioinformatics models used in this project. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The study was supported by grants from the Norwegian Research Council (grant 250864/F20), the Fritz and Ingrid Nilsen's endowment for MS research and an unrestricted research grant from Biogen Norway.